<DOC>
	<DOCNO>NCT01052480</DOCNO>
	<brief_summary>This randomize , open-label , multicenter phase 2 trial ass safety , efficacy , pharmacokinetics ( PK ) anti-influenza plasma subject influenza A B. Hospitalized subject influenza A B either low oxygen level high respiratory rate eligible study participation . This study enroll adult , child pregnant woman .</brief_summary>
	<brief_title>Safety Efficacy Investigational Anti-Influenza Immune Plasma Treating Influenza</brief_title>
	<detailed_description>Morbidity mortality occur despite treatment current antiviral . Circulating influenza H1N1 H3N2 isolate highly resistant amantadine rimantadine , whereas previous seasonal H1N1 isolate highly resistant oseltamivir . So concern circulate influenza A/H1N1 2009 virus may also acquire oseltamivir resistance . This randomized , open-label , multicenter phase 2 trial ass safety , efficacy , pharmacokinetics ( PK ) anti-influenza plasma subject influenza . Hospitalized subject influenza risk severe disease ( define inclusion criterion ) eligible study participation . This study enroll adult , child pregnant woman . Up 40 site United States participate protocol . One hundred eligible subject randomize 1:1 ratio receive either 2 unit ( pediatric equivalent ) anti-influenza immune plasma Study Day 0 addition standard care standard care alone ( 50 subject receive standard care alone ; 50 subject receive anti-influenza immune plasma standard care ) . Subjects assess Study Day 0 ( pre-dose ) , 30 minute post-dose ( plasma arm ) , Study Days 1 , 2 , 4 , 7 , 14 , 28 . All subject undergo series efficacy , safety , PK ( HAI ) assessment study . Blood sample collect time point ( except Day 1 ) . Nasal oropharyngeal swab influenza PCR obtain Days 0,1,2,4 7 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Diagnosis influenza A B prior enrollment Hospitalization sign symptom influenza ( decision hospitalization individual treating clinician ) . Abnormal respiratory status , define room air saturation oxygen ( SaO2 ) less 93 % tachypnea ( respiratory rate normal ) Agree storage specimen data ABO compatible plasma available site available within 24 hour randomization activity locally circulate strain influenza Receipt nonlicensed treatment influenza within last 2 week ( plan receive time study ) . This include licensed drug nonapproved dos , offlabel indication , drug available Emergency Use Authorization ( EUA ) . Symptoms sign acute influenzalike illness occur 7 day prior enrollment . History severe allergic reaction blood product ( judged investigator ) . Medical condition receipt 500 mL volume ( 8 mL/kg pediatric patient ) may dangerous subject ( e.g . decompensated congestive heart failure [ CHF ] , etc . ) Clinical suspicion etiology illness primarily bacterial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Antiviral</keyword>
	<keyword>Anti-Influenza Immune Plasma</keyword>
	<keyword>Emerging Infectious Disease</keyword>
	<keyword>Swine Flu</keyword>
</DOC>